EGFR and neoplasm: In the Phase III FLAURA study, Chmielecki et al. [58] identifies acquired resistance mechanisms to first-line osimertinib with NGS assessing circulating-tumor DNA from paired plasma samples (baseline and disease progression/treatment discontinuation) in patients with baseline EGFR mutation.